Jupiter Wellness, Inc.
15.7.2021 14:32:32 CEST | ACCESS Newswire | Press release
JUPITER, FL / ACCESSWIRE / July 15, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced that Dr Andy Goren has been appointed to its Scientific Advisory Board.
Dr. Andy Goren has more than twenty years of experience in clinical research, development, and commercialization of breakthrough therapeutics and diagnostics. Among his list of many firsts in dermatology, Dr. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid-test for predicting Minoxidil response in Androgenetic Alopecia.
Dr. Goren is actively involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy-induced alopecia, excessive hair shedding, female sexual dysfunction, and COVID-19. His latest research involves the use of anti-androgen therapy for the treatment of COVID-19 that was performed in conjunction with the Brazilian Government.
Dr. Goren is the President and Chief Medical Officer of Applied Biology, Irvine, CA. He is External Medical Advisor and a Co-Researcher, Trichology Unit, Ramon y Cajal Hospital, Madrid, Spain, a Visiting Professor of Dermatology, Department of Dermatology and Venereology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, a Medical Doctor at the Skin & Cosmetic Research Dept., Shanghai Skin Disease Hospital, Shanghai, China, and a Visiting Medical Doctor, Department of Dermatology and Venereology, L.T.M. Medical College Sion, Mumbai, India. Clinical Research Director at Samel Hospital, Manaus, Brazil. Dr. Goren has published dozens of peer-reviewed original medical research papers. He is an honorary as well as an ordinary member of several dermatology societies worldwide as well as a regular lecturer at dermatology congresses around the world.
"We are delighted to welcome Dr. Goren to our Scientific Advisory Board" stated Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness. "We have already established an important collaboration with him and his colleagues for our clinical programs in eczema, burns, and actinic keratosis. Andy's expertise in dermatology and widespread access to clinics worldwide will help progress the development of our skin products and provide us access to patients through his many affiliations with large dermatological hospitals around the world. More importantly, he has a unique understanding of the translation of scientific data into commercial products".
About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of skincare therapeutics and treatments. The Company's product pipeline of enhanced skincare therapeutics focuses on the endocannabinoid system to address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products including CaniSun™ sunscreen and other wellness brands sold through www.cbdcaring.com.
For additional information, please visit www.jupiterwellness.com. The Company's public filings can be found at www.Sec.gov.
Safe Harbor Statement
To the extent, any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that is based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors relating to the company's industry, its operations and results of operations, and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Investor & Public Relations Contact Info
Phone: 561-244-7100
Email: info@JupiterWellness.com
SOURCE: Jupiter Wellness, Inc.
View source version on accesswire.com:
https://www.accesswire.com/655589/Jupiter-Wellness-Announces-Appointment-of-Dr-Andy-Goren-to-Scientific-Advisory-Board
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Achieves New Milestone With Semi-Autonomous CCA Flight12.2.2026 21:55:00 CET | Press release
YFQ-42A Uncrewed Fighter Jet Executes Mission Autonomy Test SAN DIEGO, CA / ACCESS Newswire / February 12, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) passed a new milestone this month, successfully integrating 3rd-party mission autonomy into the YFQ-42A Collaborative Combat Aircraft to conduct its first semi-autonomous airborne mission. For this test, GA-ASI used mission autonomy software supplied by Collins Aerospace, an RTX business, to fly the new YFQ-42A CCA, designed and developed by GA-ASI for the U.S. Air Force. The Sidekick Collaborative Mission Autonomy software was seamlessly integrated with the YFQ-42A's flight control system, utilizing the Autonomy Government Reference Architecture (A-GRA). The integration enabled robust and reliable data exchange between the autonomy software and the aircraft's mission systems, ensuring precise execution of mission autonomy commands. During the recent testing, autonomy mode was activated via the Ground Station Console (GSC)
Loar Holdings Inc. Announces Date and Time for Fourth Quarter and Full Year 2025 Earnings Conference Call12.2.2026 14:30:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / February 12, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q4 and Full Year 2025 earnings before the market opens on Thursday, February 26, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar
U.S. Polo Assn. Unveils Experiential USPA Shop Flagship at the USPA National Polo Center12.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FLORIDA / ACCESS Newswire / February 12, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), announces the reopening of its experiential USPA Shop Flagship at the USPA National Polo Center (NPC) in Wellington, Florida. The sports brand is introducing a reimagined retail destination that reflects the brand's deep connection to the sport of polo and its modern global positioning.The USPA Shop Flagship at the USPA National Polo Center Photo Credit: Augustina Fonda The USPA Shop at NPC now places a strong emphasis on the guest experience. Inside and out, the space is complemented by refined visuals, immersive activations, curated sound, a signature scent, and a best-in-class assortment of apparel and accessories from the brand's design hubs of New York, London, Florence, and Istanbul. The refreshed design of the flagship location blends heritage, sport, and contemporary style, incorporating signature U.S. Polo Assn. elements such
Fidelity Investments Upgrades FINOS Membership to Platinum, Reinforcing Its Strategic Commitment to Open Source Collaboration in Financial Services11.2.2026 15:00:00 CET | Press release
Following its leadership in launching Fluxnova, Fidelity's appointment to the FINOS Governing Board underscores the growing recognition of the ROI of open source for all market participants NEW YORK CITY, NY / ACCESS Newswire / February 11, 2026 / The Fintech Open Source Foundation (FINOS), the foundation of open innovation in financial services, today announced that Fidelity Investments has upgraded its FINOS membership to Platinum, reflecting Fidelity's deepening strategic commitment to open source collaboration, industry interoperability, and the responsible adoption of emerging technologies such as AI across regulated financial services. The membership upgrade builds directly on Fidelity's role in the formation of Fluxnova, a FINOS-hosted open source orchestration platform created to address critical industry needs around workflow automation, vendor independence, and long-term infrastructure sustainability. Fidelity spearheaded the project's contribution into FINOS, helping establi
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program10.2.2026 21:00:00 CET | Press release
GA-ASI's YFQ-42A Platform to Support Next-Generation Expeditionary Air Operations SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 10, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) was competitively selected by the U.S. Marine Corps (USMC) for evaluation in the Marine Air-Ground Task Force Uncrewed Expeditionary Tactical Aircraft (MUX TACAIR) Collaborative Combat Aircraft (CCA) program. The agreement integrates GA-ASI's expertise in autonomy and uncrewed aircraft systems with a government-provided mission package, usingthe YFQ-42A platform as a surrogate to evaluate integration with crewed fighters. The contract initiates integration of a Marine Corps mission kit into the YFQ-42A surrogate platform for assessment within the Marine Air Ground Task Force (MAGTF). The USMC contract includes the rapid development of autonomy for the government-supplied mission kit - a cost-effective, sensor-rich, software-defined suite capable of delivering kinetic and non-kinetic effects -
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
